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Abstract
A new study shows that fasting induces the differentiation and elimination of some types of 
leukemia, which implicates fasting or its mimetics as a novel strategy for the treatment of 
leukemia.
Acute leukemias, characterized by the excess production of hematopoietic progenitor cells 
of the lymphoid (acute lymphoblastic leukemia, ALL) or myeloid lineages (acute myeloid 
leukemia, AML), are among the most common causes of childhood cancer worldwide. Both 
ALL and AML are challenging to treat because subsets of patients fail to respond to 
conventional therapies, such as chemotherapy or radiation, as well as to targeted therapies, 
such as tyrosine-kinase inhibitors and bone marrow transplantation1. In this issue of Nature 
Medicine, Lu et al.2 explore the therapeutic potential of fasting (i.e., food deprivation 
without water restriction), a dietary intervention that has been previously proposed to 
promote normal hematopoietic regeneration3, as a treatment for acute leukemia. Their 
findings reveal that periodic fasting selectively inhibits the development of ALL, but not 
AML, by upregulating the leptin receptor (LEPR) protein and its downstream effector PR-
domain zinc-finger protein 1 (PRDM1).
Similar to normal hematopoiesis, leukemia often follows a hierarchy whereby primitive, 
self-renewing leukemia-propagating cells give rise to bulk leukemic blast cells1. Unlike 
normal hematopoietic cells, leukemic blast cells are blocked at an early stage of their 
development and fail to differentiate into mature, functional hematopoietic cells. In acute 
leukemia, neoplastic progenitors proliferate and overrun normal hematopoietic cells of the 
marrow, spleen and peripheral blood, and eventually, they reduce blood cell counts. 
Accordingly, therapeutic strategies that force cancer cells to resume the process of lineage 
maturation have been proposed as an alternative approach to cytotoxic chemotherapy for 
eliminating cancer cells such as leukemia. However, despite the success of all-trans-retinoic 
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acid (ATRA) in the treatment of acute promyelocytic leukemia (APL), which enables the 
differentiation of APL leukemic blast cells, only a limited number of pharmacological 
agents that drive the terminal differentiation of leukemic cells have been identified4. Lu et 
al.2 turned their attention to dietary approaches for inducing the differentiation of leukemia 
cells. The authors first investigated the effects of fasting on ALL and AML development 
using mouse models of acute leukemia. In these models, fluorescence-tagged and 
oncogenic-engineered cancerous precursors were generated in vitro and then transplanted 
into immune-compromised mice to generate acute leukemia (Fig. 1). The mice then 
underwent cycles of fasting during leukemogenesis. Notably, the authors found that early 
fasting was sufficient to prevent the initiation, and to almost completely prevent the 
development, of both B cell and T cell ALLs. Fasting not only had a strong inhibitory 
impact on the early growth of ALLs, but was also quite effective at reducing leukemia 
progression at later stages associated with high disease burden. This finding raises the 
possibility that fasting or its pharmacological mimetics might have a role in treating patients 
that have advanced leukemia. Notably, the effects of fasting were found to be cancer-type 
dependent; in contrast to ALL, fasting cycles had negligible effects on AML.
In response to fasting, ALL cells demonstrated rapid proliferation, apoptosis and 
differentiation. To gain more mechanistic insight into how fasting might eliminate ALL 
cells, the authors carried out RNA-sequencing and pathway analysis and found a prominent 
signature indicative of LEPR signaling in these cells, including strong activation of PRDM1. 
PRDM1 is a downstream target of LEPR-mediated STAT signaling that drives the terminal 
differentiation of lymphoid progenitors. The authors propose that fasting upregulates the 
expression of LEPR and its downstream transcription factor PRDM1and that this process 
enables ALL blast cells to differentiate (Fig. 1). The authors reveal that LEPR expression 
was reduced upon the development of ALL but not that of AML. Furthermore, they show 
that attenuation of LEPR signaling is essential for the maintenance of ALL, but not of AML, 
in two mouse models of obesity, which indicates that the activation of LEPR signaling 
underlies the fasting-induced inhibition of ALL growth. Although it remains unclear 
whether fasting universally inhibits the development of most ALLs—even those with 
different genetic drivers than those tested in these mouse models—the authors provide 
convincing evidence that fasting-induced LEPR signaling might mitigate disease burden in 
some types of ALL.
Dietary interventions have been applied successfully to treat certain solid cancers in animal 
models5. For example, periodic fasting sensitizes a wide range of xenograft tumor models, 
such as melanoma, glioma and breast cancer, to chemotherapy6. Furthermore, recent studies 
focused on the hematopoietic and immune systems illustrate that fasting or fasting mimetics 
enhance antitumor immunity, which results in delayed progression of breast cancer and 
melanoma in preclinical models3,7. However, whether these findings apply to humans is 
unknown.
As an alternative to dietary interventions, another approach might be to co-opt pathways 
activated by such interventions with pharmacologic agents. In this study, Lu et al.2 show that 
in patients with pediatric pre-B-ALL, LEPR signaling is highly associated with the 
prognosis of the disease. Fasting-induced LEPR signaling, for instance, effectively inhibits 
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human B-ALL disease development in xenograft assays. Additionally, overexpression of 
LEPR or its effector PRDM1 in mouse models of ALL recapitulated the ability of fasting to 
promote the differentiation of ALL cells. Collectively, these results suggest that fasting-
induced LEPR and PRDM1 signaling can be exploited therapeutically for the treatment of 
ALL.
Leptin, a hormone known for its role in satiety, held hope as a treatment for obesity; 
however, treatments involving leptin failed in part owing to the development of leptin 
resistance, which is associated with high levels of leptin, low levels of LEPR and diminished 
sensitivity to the hormone8. It was then proposed that the reversal of leptin resistance might 
improve the treatment of obesity. Notably, as reported by Lu et al.2, fasting reduces leptin 
levels while boosting LEPR signaling in ALL (i.e., it enhances leptin sensitivity). The use of 
leptin sensitizers, such as withaferin A or metaformin, might represent an effective 
alternative to mimic the antitumor effects of fasting in the treatment of ALL9. However, just 
as AML and ALL have different requirements for LEPR-signaling in their maintenance, 
such differences might also exist across other tissues, cell lineages or even between normal 
and cancerous cells; therefore, it will be important to decipher the potential toxicities of 
fasting or of LEPR-based therapies.
Recent studies indicate that, in response to therapy, a subset of acute leukemias can switch 
lineages or acquire mixed lineage phenotype (i.e., they possess both myeloid and lymphoid 
features) at relapse, which might permit such leukemias to escape fasting- or LEPR-induced 
differentiation10. Thus, proposed therapeutic interventions will need to overcome such 
complications or mechanisms of escape. Despite these potential challenges, this study 
identifies an important role for LEPR and PRDM1 signaling in leukemic cell differentiation 
that might one day be exploited therapeutically to reduce disease burden in patients with 
ALL.
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Figure 1. 
Fasting regulates LEPR-mediated leukemia differentiation. Fluorescence-tagged 
preleukemic acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) cells 
are transplanted into recipient mice. As leukemia develops in the mice, ALL cells express 
low levels of LEPR. However, Lu et al.2 show that fasting induces LEPR expression, which 
leads to the activation of its downstream effector PRDM1. This fasting-induced gene-
expression program, at early stages, prevents the development of leukemia, and at later 
stages, drives the differentiation and eventual depletion of leukemic cells. By contrast, AML 
cells express high levels of LEPR and are refractory to the effects of fasting.
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